60 / 210
XXXII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia
60
third day pharmacokinetic-guided prophylaxis. Haemophilia 2016;1.
DOI: 10.1111/hae.12905. [Epub ahead of print].
22. Den Uijl JE, Mauser Bunschoten EP, Roosendaal G, Fischer K. Cli-
nical severity of haemophilia A: does the classification of the 1950s
still stand? Haemophilia 2011;17:84953.
23. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-
up of dosing, coagulation factor levels and bleedings in relation to
joint status in the prophylactic treatment of haemophilia. Haemo-
philia 2004;10(6):689-97.
24. Lindvall K, Astermark A, Björkman S, Ljung R, Carlsson KS,
Perssons S, et al. Daily dosing prophylaxis for haemophilia: a ran-
domized crossover pilot study evaluating feasibility and efficacy.
Haemophilia 2012;18(6):855-9
25. Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka SA,
Schrothe P, et al. A randomized comparison of two prophylaxis
regimens and a paired comparison of on-demand and prophylaxis
treatments in hemophilia A management. J Thromb Haemost
2012;10:359-67.
26. Berntorp E, Dolan G, Hermans C, Laffan M, Santagostino E,
Tiede A. Pharmacokinetics, phenotype and product choice in
haemophilia B: how to strike a balance? Haemophilia 2014;20
(Suppl. 7),1-11
27. Brekkan A, Berntorp E, Jensen K, Nielsen EI, Jönsson S. Popula-
tion Pharmacokinetics of Plasma-Derived Factor IX: Procedures for
Dose Individualization. J Thromb Haemost 2016;25. DOI: 10.1111/
jth.13271. [Epub ahead of print]